Cencora (COR) Economic Moat Analysis44

Moat44

Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.

structural advantage · 2/4 · The geographic distribution footprint, primary-supplier role and realized volume growth establish scale and operational relevance. These support a plausible cost mechanism, but no relative cost benchmark, purchasing advantage or replication barrier is supplied. Scale alone therefore supports a mixed structural assessment rather than a demonstrated durable moat.

durability · 1/4 · Primary-supplier relationships and increased sales to major customers support persistence, but annual contract expirations and an actual oncology non-renewal show that relationships remain contestable. The catalog supplies little evidence of barriers that preserve superior economics over time. This grades the durability evidence as fragile without asserting that every relationship is weak.

customer dependency · 2/4 · Being the typical primary supplier indicates meaningful participation in customers’ recurring operations, and increased sales to the two largest customers provide indirect repeat-demand evidence. Oncology and grocery customer losses demonstrate alternatives in practice. No migration costs or disruption measures establish stronger dependency.

erosion resilience · 2/4 · U.S. revenue grew despite manufacturer-price declines and customer losses, while international operating income increased over the quarter and nine-month period. These are realized offsets to erosion. Market volume growth and external manufacturer pricing explain part of the performance, so resilience cannot confidently be attributed to a protected competitive position.

Pricing power—

Insufficient evidence for every rubric criterion; no category score is inferred.

realized pricing · 1/4 · Manufacturer-price declines reduced U.S. revenue, while manufacturer increases supported international quarterly operating income. These observed outcomes demonstrate fragile, externally driven product-price exposure. Volume growth is separately identified. The evidence supports a weak pricing assessment but does not isolate changes in Cencora’s own distribution fees or establish their direction.

retention · 2/4 · Primary-supplier status and increased sales to the two largest customers support recurring demand, assessed indirectly from operating disclosures. Actual oncology and grocery customer losses offset that evidence. Product-demand growth can raise sales without improving retention, and no retention rate or completed major supply extension is supplied here.

margin resilience · 2/4 · International operating income increased 20.8% for the quarter and 5.9% for the nine months ended June 30, 2026. Specialty logistics contributed, while manufacturer-price increases helped the quarter. This supports bounded earnings resilience, but does not establish consolidated margin stability or demonstrate that Cencora protected economics through its own pricing decisions.

contractual freedom · — · Annual customer-contract expirations and exposure to manufacturer-price changes are disclosed, but they do not establish who controls distribution fees, repricing provisions or customer terms. Competitive pressure is described as a risk rather than a specific contractual restriction. The supplied catalog cannot support a grade for contractual pricing freedom.

Predictability100

5 consecutive published annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.

Nondeclining revenue years (%)

100.00

Revenue growth volatility (pp)

1.15

Positive FCF years (%)

100.00

FCF margin volatility (pp)

0.13

observedAnnualPeriods

5.00

Financial strength64

Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or reported pretax profit plus reported gross interest expense. Reported EBIT is distinct from GAAP operating income and gross interest. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.

debtFcfGrade

80.16

netDebtEbitGrade

74.86

interestCoverageGrade

89.73

currentRatioGrade

12.28

Debt / FCF (x)

2.39

Net debt / operating income (x)

1.26

Current ratio (x)

0.90

cashInterestPaid

356.50

cashInterestCoverage

10.87

Capital allocation100

Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or EBIT calculated from reported pretax profit plus reported gross interest expense; the issuer-reported EBIT is distinct from GAAP operating income and gross interest; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. ROIC remains undefined for nonpositive invested capital; the explicit asset-return alternative does not change the ROIC chart. Missing financial inputs alone never trigger an alternative. Does not establish acquisition quality or buyback timing.

3-year pre-tax operating return (%)

84.01

3-year average dilution (%)

-2.40

3-year average SBC / revenue (%)

0.05

cashConversionGrade

100.00

Management56

Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.

capital discipline · 2/4 · Completed OneOncology consideration and debt-and-cash financing, together with fiscal 2025 repurchases, show actual deployment decisions. PharmaLex goodwill impairments of $723.9 million in fiscal 2025 and $418.0 million in fiscal 2024 materially temper discipline. The catalog does not establish satisfactory long-term acquisition returns or sufficient cash-flow coverage for a stronger grade.

incentive alignment · 3/4 · Fiscal 2025 granted incentives include adjusted ROIC and a relative-TSR modifier, supplemented by post-vesting holding requirements, actual executive ownership compliance and a hedging prohibition. These demonstrate substantial alignment structures. Eligible holdings include time-vested RSUs, and adjusted cash flow excludes certain legal settlements; realized payout discipline is not established.

execution · 2/4 · Realized U.S. revenue growth, international operating-income growth and completion of OneOncology support execution, partly through indirect operating evidence. Actual customer losses and repeated PharmaLex impairments offset these achievements. Market demand and manufacturer pricing explain some growth, and acquisition completion does not demonstrate successful integration or durable returns.

governance · 2/4 · Disclosed independent key committees and the completed transition from Lead Independent Director to Board Chair support functioning oversight structures. The $4.2 billion opioid-related settlement liability at June 30, 2026 is a material adverse legacy outcome. These support a mixed assessment without attributing historical conduct to current directors or assuming an unsupplied audit conclusion.